Trial Profile
A Phase I, Open Label, Multicenter, Parallel-group, Single Dose Two-staged Study to Evaluate the Pharmacokinetics and Safety of a Single 400 mg Oral Dose of LEE011 in Subjects With Varying Degrees of Impaired Renal Function Compared to Matched Healthy Volunteers With Normal Renal Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ribociclib (Primary)
- Indications Breast cancer; Cancer; Liposarcoma; Lymphoma; Non-small cell lung cancer; Soft tissue sarcoma
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 20 Aug 2018 Status changed from recruiting to completed.
- 05 Jun 2018 Planned End Date changed from 4 May 2018 to 17 Aug 2018.
- 10 Nov 2017 Planned End Date changed from 30 Oct 2017 to 4 May 2018.